RBD

RBD
Name	RBD
Field	Neurology, Sleep medicine

RBD Rapid eye movement sleep behavior disorder (commonly abbreviated RBD) is a parasomnia characterized by loss of normal muscle atonia during rapid eye movement REM sleep with enactment of dreams. It is important in clinical neurology and sleep medicine because of its strong association with neurodegenerative disorders and its implications for safety, forensic evaluation, and longitudinal prognosis. Research on RBD intersects with neurology, psychiatry, geriatrics, and sleep laboratories in institutions such as Mayo Clinic, Johns Hopkins Hospital, Stanford University School of Medicine, and Harvard Medical School.

Definition and terminology

RBD is defined by repeated episodes of complex motor behaviors arising from REM sleep, accompanied by dream mentation and concurrent polysomnographic evidence of REM sleep without atonia. Diagnostic criteria have been codified by organizations including the American Academy of Sleep Medicine and the International Classification of Sleep Disorders. Terms historically used include "REM sleep behavior disorder" and descriptions in older literature from centers such as Montreal Neurological Institute and National Institutes of Health sleep centers; contemporary usage emphasizes idiopathic RBD and secondary RBD when linked to medications or lesions.

Epidemiology and demographics

Population studies from cohorts in Europe, North America, and Asia indicate prevalence estimates vary, with higher rates in older adults and among males. Community-based screenings and sleep-clinic series from Sweden, Japan, United Kingdom, and United States show prevalence ranges from under 1% in middle-aged populations to several percent in cohorts aged over 60 years. Case series from tertiary centers such as Karolinska Institute and University College London report male predominance, whereas selected cohorts in clinics at Massachusetts General Hospital and Cleveland Clinic include more balanced sex distributions when accounting for milder presentations. Longitudinal cohorts from institutions like University of Barcelona and University of Toronto have been instrumental in defining incidence and conversion rates to neurodegenerative syndromes.

Pathophysiology and causes

Pathophysiology implicates dysfunction of pontine and medullary structures that normally suppress motor activity during REM sleep, with involvement of nuclei and pathways studied in models from Columbia University and University of California, San Diego. Neurotransmitter systems implicated include monoaminergic and cholinergic networks researched at King's College London and University of Oxford. Idiopathic RBD is frequently a prodrome of synucleinopathies, especially Parkinson's disease, Dementia with Lewy bodies, and Multiple system atrophy. Secondary causes include medications (e.g., antidepressants), structural lesions described in case reports from Mayo Clinic and Bern University Hospital, and paraneoplastic or autoimmune conditions investigated by teams at Institut Pasteur and Johns Hopkins University School of Medicine.

Clinical features and diagnosis

Clinically, patients present with vivid, often action-filled dreams and complex motor behaviors such as punching, kicking, or shouting that may injure the patient or bed partner. Typical history-taking references protocols developed at Veterans Affairs Boston Healthcare System and assessment tools from University of Michigan and Toronto Western Hospital. Diagnosis requires video-polysomnography demonstrating REM sleep without atonia, as standardized in guidelines from American Academy of Sleep Medicine and laboratory networks affiliated with World Sleep Federation. Ancillary testing may include neurological examination for parkinsonism following criteria from Movement Disorder Society and neuroimaging such as dopamine transporter SPECT used in studies at Karolinska Institute and Radboud University Medical Center.

Differential diagnosis

Differential considerations include nocturnal seizures (temporal lobe epilepsy described in reports from Mayo Clinic and Cleveland Clinic), non-REM parasomnias such as sleepwalking and confusional arousals noted in cohorts at University of Oxford and Sapienza University of Rome, dissociative or psychiatric mimics reported by teams at Columbia University and Yale School of Medicine, and medication-induced motor phenomena cataloged in databases at Utrecht University and University of Amsterdam. Distinguishing features involve timing within the sleep cycle, EEG correlates, and the presence of dream recall as emphasized in consensus statements from International RBD Study Group.

Management and treatment

Management focuses on injury prevention, pharmacotherapy for symptomatic control, and addressing underlying causes. Safety measures and environmental modifications draw on recommendations from National Sleep Foundation and hospital safety protocols at Massachusetts General Hospital. First-line pharmacologic agents with evidence from randomized and open-label studies at Mayo Clinic, King's College Hospital, and University of Tokyo include clonazepam and melatonin; choice is individualized based on comorbidity profiles defined by guidelines from American Academy of Sleep Medicine and reviews in journals affiliated with European Academy of Neurology. Withdrawal or adjustment of culprit medications, treatment of comorbid sleep apnea as per American Thoracic Society guidance, and multidisciplinary follow-up with neurologists from centers such as Johns Hopkins Hospital are often recommended.

Prognosis and complications

Longitudinal cohorts from Barcelona, Paris', and Helsinki indicate that idiopathic cases often progress to synucleinopathies over years to decades, with conversion rates estimated in multicenter registries coordinated by groups including International RBD Study Group and research consortia at National Institute of Neurological Disorders and Stroke. Complications include injury to patients or bed partners, sleep fragmentation, daytime somnolence, and psychological distress documented in clinic series from University of California, Los Angeles and University of Melbourne. Prognosis varies by age, sex, and biomarkers such as dopaminergic imaging abnormalities studied at Karolinska Institute and Baylor College of Medicine.

Category:Sleep disorders